JNJ vs PTGX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
JNJ is the larger of the two ($651.09B market cap): the incumbent the market prices for continued execution (23.29x forward earnings, beta 0.20). PTGX is the smaller challenger ($8.00B), actually pricier on forward earnings (351.94x): more room to run, but more to prove. On the numbers, JNJ leads on both counts: faster expected revenue growth (6% vs -58%) and a lower forward P/E (23.29x vs 351.94x). The case for PTGX rests on its own driver (Icotrokinra (ICOTYDE) launch with J&J): if you believe in that, PTGX fits; if you believe in what the numbers show today, JNJ does.
JNJ vs PTGX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | JNJ | PTGX | What it tells you |
|---|---|---|---|
| Market cap | $651.09B | $8.00B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 23.29 | 351.94 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 41.04 | 25.90 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.20 | 1.22 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 78% of range | 54% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.99 | 7.36 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: JNJ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how JNJ and PTGX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and PTGX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and PTGX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Johnson & Johnson (JNJ) do?
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.
What does Protagonist Therapeutics (PTGX) do?
Protagonist Therapeutics is a Newark, California biotech that discovers oral and injectable peptide-based drugs and develops them mostly through large-pharma partners. Its two lead assets define the company: icotrokinra, an oral IL-23 receptor antagonist licensed to Johnson & Johnson and launched in the U.S. in March 2026 (branded ICOTYDE) for moderate-to-severe plaque psoriasis, and rusfertide, a once-weekly injectable hepcidin mimetic licensed to Takeda that the FDA approved in August 2026 as MIMRYLO for erythrocytosis in adults with polycythemia vera. ICOTYDE has since also been approved in China, Japan and the EU. Behind those, the pipeline includes an oral IL-17 antagonist (PN-881), an oral hepcidin functional mimetic (PN-8047), and obesity dual and triple agonists such as PN-477, most still in early stages.
JNJ vs PTGX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
- PTGX drivers: Icotrokinra (ICOTYDE) launch with J&J; MIMRYLO (rusfertide) launch with Takeda.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For PTGX, as a partner-dependent biotech, Protagonist has limited control over commercial execution: ICOTYDE's uptake and MIMRYLO's launch sit largely with J&J and Takeda, and Protagonist no longer controls MIMRYLO's pricing, market access or commercial investment.
JNJ or PTGX: which should you pick?
If the story you believe is JNJ's (Innovative Medicine pipeline), JNJ is the more direct way to own it; if it is PTGX's (Icotrokinra (ICOTYDE) launch with J&J), PTGX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and PTGX guides.
JNJ vs PTGX: the full fundamentals
JNJ. J&J's trailing P/E near 41 is inflated by a third quarter in which GAAP net income fell to about $210 million on items excluded from adjusted results; on forward estimates (about $11.61 of EPS for 2027) the multiple is near 23. That is a premium to where the stock traded early in 2026, after a roughly 30% year-to-date rise, and the dividend yield has compressed to about 2.0%. The market is paying for steady mid single-digit growth, high margins, strong cash generation and a raised 2026 outlook, still with some discount for litigation and patent-cliff overhangs; figures are approximate as of November 20, 2026.
PTGX. As of November 2026, revenue is dominated by milestone and collaboration payments, including Takeda's $200 million initial opt-out payment in Q2 and the further $200 million opt-out fee plus $75 million MIMRYLO approval milestone recognized mostly in Q3. That lifted trailing twelve-month net income to about $342 million and the trailing P/E to a modest-looking 26x, but consensus sees 2027 revenue near $236 million and EPS of only about $0.35, which is why the forward P/E of about 350x says little either. The valuation is really a bet on the royalty streams from ICOTYDE and MIMRYLO; the average analyst target is about $182 (14 analysts), and UBS initiated at Buy with a $184 target in October 2026.
Headline figures (approximate, November 2026): JNJ shows revenue (ttm) ~$99 billion, q3 2026 sales ~$25.4 billion (+~6% YoY), q3 2026 adjusted eps $2.59 (vs ~$2.52 est.), operating margin ~27%; PTGX shows market cap ~$8.0B, share price ~$121.85 (up ~40% YTD, ~45% over one year), revenue (ttm) ~$552M, q3 2026 revenue ~$274.4M (~$266.6M from the Takeda opt-out fee and MIMRYLO milestone).
The bottom line: JNJ vs PTGX
JNJ and PTGX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined JNJ and PTGX exposure against your real portfolio. It is not an investment adviser.
Wondering how JNJ or PTGX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Johnson & Johnson
Ask Walnut's AI anything about JNJ and see how it fits what you own.
FAQ
What is the difference between JNJ and PTGX?
+
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Protagonist Therapeutics is a Newark, California biotech that discovers oral and injectable peptide-based drugs and develops them mostly through large-pharma partners. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is JNJ or PTGX the better stock?
+
Neither is universally better. JNJ is the larger incumbent; PTGX is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, JNJ or PTGX?
+
On forward P/E (as of November 2026), JNJ trades at 23.29x and PTGX at 351.94x, so JNJ is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both JNJ and PTGX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of JNJ vs PTGX?
+
JNJ: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. Drug pricing pressure, including US government negotiation of certain drug prices, can weigh on margins. The company also faces significant legal liability, most notably ongoing litigation related to talc-based products, which has created uncertainty and large potential settlements. MedTech competes in tough device markets and is exposed to hospital budgets and procedure volumes. Regulatory, clinical-trial, and product-safety risks are inherent to healthcare. International pricing pressure weighed on third-quarter 2026 results, and large items outside adjusted earnings cut GAAP net income to about $210 million that quarter. Growth is steady rather than rapid, yet after a roughly 33% one-year rise the stock trades near 23 times forward earnings, so valuation now leaves less cushion than it did when J&J traded in the mid-teens. PTGX: As a partner-dependent biotech, Protagonist has limited control over commercial execution: ICOTYDE's uptake and MIMRYLO's launch sit largely with J&J and Takeda, and Protagonist no longer controls MIMRYLO's pricing, market access or commercial investment. Slow psoriasis or polycythemia vera launch traction, weak payer access, or disappointing later-stage data in psoriatic arthritis or inflammatory bowel disease could remove large chunks of the royalty value the stock currently prices in. Much of 2026's revenue is lumpy, one-time milestone and opt-out income, so analysts expect revenue to drop to about $236 million and EPS to about $0.35 in 2027, with a small loss expected in Q4 2026. The early pipeline, including obesity agonists, is unproven and competes against far larger, better-funded programs. An insider sold about $18.2 million of shares in September 2026, per an SEC filing. Valuation near an $8.0 billion market cap, roughly 14x trailing revenue and about 350x 2027 consensus earnings, already embeds substantial future success, and the shares are about 24% below their 52-week high of $160.81 after falling about 12% in the month to November 20, 2026, a reminder of how sharply they can move.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell JNJ or PTGX; figures are approximate and dated (as of November 2026). Verify current data before investing.